A realistic fiber protocol for GLP-1 users looks like this
The most commonly reported side effects of retatrutide in clinical trials are gastrointestinal, including nausea, vomiting, diarrhoea, constipation, and decreased appetite, consistent with other GLP-1-based therapies
On its own, GLP-1 does several useful things
In fact, FDA has identified some areas of concern for compounded GLP-1 drugs and is working with its state regulatory partners regarding them
It is mainly found in indigenous to Europe, western Asia, and North America
This high-stakes environment puts enormous pressure on stakeholders to innovate quickly while also preparing for what comes next: reinvention as biosimilars and new competitors disrupt the landscape